Bellevue Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bellevue Group’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-25,000	Closed	-$1.54M	–	219
2019 Q4	$1.54M	Buy	+25,000	New	+$1.33M	0.02%	141
2017 Q3	–	Sell	-19,000	Closed	-$1.01M	–	132
2017 Q2	$1.01M	Buy	+19,000	New	+$927K	0.12%	102
2017 Q1	–	Sell	-20,500	Closed	-$818K	–	133
2016 Q4	$818K	Sell	20,500 -25,000	-55%	-$1.07M	0.17%	94
2016 Q3	$2.21M	Buy	45,500 +25,000	+122%	+$1.19M	0.4%	72
2016 Q2	$796K	Buy	20,500 +2,500	+14%	+$108K	0.15%	103
2016 Q1	$736K	Buy	+18,000	New	+$796K	0.13%	101

Other funds holding BIB

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

SBIA

Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SkyOak Wealth Southfield, Michigan $546M AUM 18.14% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Trexquant Investment Stamford, Connecticut $13.9B AUM 31.98% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Bellevue Group's BIB Position: Q1 2020 in Review

Bellevue Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2020, closing a stake of 25,000 shares — an estimated $1.54M sold.

Bellevue Group first reported a position in BIB in Q1 2016 and held it in 6 quarters. The position peaked at $2.21M in Q3 2016. 26 funds tracked by Wall St. Rank hold BIB as of Q1 2020.

Bellevue Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
Bellevue Group sold 25,000 ProShares Ultra NASDAQ Biotechnology shares in Q1 2020, an estimated $1.54M.
Bellevue Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2016 and held it in 6 quarters.
Bellevue Group's ProShares Ultra NASDAQ Biotechnology position peaked at $2.21M in Q3 2016.
26 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2020.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.